Galectin Operating Income from 2010 to 2024

GALT Stock

USD 1.04 0.96 48.00%

Galectin Therapeutics Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Galectin Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2001-03-31

Previous Quarter

-11.3 M

Current Value

-9.1 M

Quarterly Volatility

2.9 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Galectin Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galectin Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 40 M, Interest Expense of 2.7 M or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0016 or Days Sales Outstanding of 0.0. Galectin financial statements analysis is a perfect complement when working with Galectin Therapeutics Valuation or Volatility modules.

Check out the analysis of Galectin Therapeutics Correlation against competitors.

For more information on how to buy Galectin Stock please use our How to Invest in Galectin Therapeutics guide.

Latest Galectin Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Galectin Therapeutics over the last few years. Operating Income is the amount of profit realized from Galectin Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Galectin Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Galectin Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galectin Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Galectin Operating Income Regression Statistics

	Arithmetic Mean	(19,938,293)
	Coefficient Of Variation	(57.04)
	Mean Deviation	9,094,313
	Median	(16,247,000)
	Standard Deviation	11,373,476
	Sample Variance	129.4T
	Range	38.2M
	R-Value	(0.89)
	Mean Square Error	28.4T
	R-Squared	0.80
	Slope	(2,269,331)
	Total Sum of Squares	1811T

Galectin Operating Income History

	2024	-36.2 M
	2023	-38.1 M
	2022	-38.4 M
	2021	-30.2 M
	2020	-23.4 M
	2019	-13.4 M
	2018	-13.6 M

Other Fundumenentals of Galectin Therapeutics

Non Operating Income Net Other

Galectin Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.25	-0.32	-0.5	0.25	0.2	1.0	-0.51	0.68	-0.03	-0.46	0.01	0.33	0.69	0.79	0.78	-0.67
Total Stockholder Equity	0.25		-0.99	0.55	-0.83	-0.89	0.26	-0.11	-0.22	0.31	0.03	0.75	0.94	-0.27	0.06	0.12	0.35
Net Debt	-0.32	-0.99		-0.52	0.8	0.86	-0.33	0.18	0.18	-0.26	-0.03	-0.77	-0.94	0.23	-0.09	-0.15	-0.32
Retained Earnings	-0.5	0.55	-0.52		-0.83	-0.8	-0.49	0.39	-0.89	0.24	0.6	0.58	0.56	-0.89	-0.6	-0.54	0.83
Accounts Payable	0.25	-0.83	0.8	-0.83		0.97	0.24	-0.04	0.56	-0.26	-0.34	-0.86	-0.7	0.61	0.39	0.33	-0.71
Total Liab	0.2	-0.89	0.86	-0.8	0.97		0.19	-0.11	0.52	-0.31	-0.25	-0.83	-0.78	0.57	0.33	0.27	-0.68
Total Current Assets	1.0	0.26	-0.33	-0.49	0.24	0.19		-0.51	0.67	-0.03	-0.45	0.02	0.34	0.68	0.79	0.78	-0.66
Short Term Debt	-0.51	-0.11	0.18	0.39	-0.04	-0.11	-0.51		-0.42	0.55	0.47	-0.1	-0.02	-0.33	-0.34	-0.35	0.25
Common Stock	0.68	-0.22	0.18	-0.89	0.56	0.52	0.67	-0.42		0.01	-0.56	-0.21	-0.28	0.99	0.76	0.71	-0.86
Property Plant Equipment	-0.03	0.31	-0.26	0.24	-0.26	-0.31	-0.03	0.55	0.01		0.32	0.19	0.33	0.04	0.27	0.3	-0.04
Current Deferred Revenue	-0.46	0.03	-0.03	0.6	-0.34	-0.25	-0.45	0.47	-0.56	0.32		0.2	0.11	-0.5	-0.3	-0.28	0.34
Net Receivables	0.01	0.75	-0.77	0.58	-0.86	-0.83	0.02	-0.1	-0.21	0.19	0.2		0.57	-0.26	-0.22	-0.2	0.43
Net Tangible Assets	0.33	0.94	-0.94	0.56	-0.7	-0.78	0.34	-0.02	-0.28	0.33	0.11	0.57		-0.28	0.13	0.2	0.3
Capital Surpluse	0.69	-0.27	0.23	-0.89	0.61	0.57	0.68	-0.33	0.99	0.04	-0.5	-0.26	-0.28		0.76	0.7	-0.88
Net Invested Capital	0.79	0.06	-0.09	-0.6	0.39	0.33	0.79	-0.34	0.76	0.27	-0.3	-0.22	0.13	0.76		0.99	-0.86
Net Working Capital	0.78	0.12	-0.15	-0.54	0.33	0.27	0.78	-0.35	0.71	0.3	-0.28	-0.2	0.2	0.7	0.99		-0.8
Capital Stock	-0.67	0.35	-0.32	0.83	-0.71	-0.68	-0.66	0.25	-0.86	-0.04	0.34	0.43	0.3	-0.88	-0.86	-0.8

Click cells to compare fundamentals

About Galectin Therapeutics Financial Statements

Galectin Therapeutics shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Galectin Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Galectin Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Galectin Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-38.1 M	-36.2 M
Non Operating Income Net Other	75.9 K	79.7 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Galectin Stock Analysis

When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Galectin Operating Income from 2010 to 2024

Latest Galectin Therapeutics' Operating Income Growth Pattern

Galectin Operating Income Regression Statistics

Galectin Operating Income History

Other Fundumenentals of Galectin Therapeutics

Galectin Therapeutics Operating Income component correlations

About Galectin Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Galectin Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY